Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Eisai Inc.

Overview

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Study Type

EXPANDED_ACCESS

Conditions

Epilepsies, Myoclonic Drug Resistant Epilepsy

Interventions

LorcaserinDRUG

Lorcaserin 10 milligram (mg) tablets orally.

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician) 2. Male or female, age at least 2 years at the time of informed consent 3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304 4. Has a clinical benefit from lorcaserin in the opinion of the treating physician Exclusion Criteria: None

Locations (22)

University of Alabama at Birmingham

Central Contacts

Eisai Medical Information

CONTACT

+1-888-274-2378 esi_medinfo@eisai.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.